Skip to content

All Press Releases

PILA PHARMA INFORMS OF OPTIMIZATION CHANGES TO TRIAL PLAN

Malmö, 17 October 2024 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO:PILA) today announces it has chosen to alter the operational plan for its next clinical trial, PP-CT03, a phase 2a safety and tolerability trial in people living with obesity and type 2 diabetes.  On 25 July, PILA PHARMA entered into agreement with a UK…

Read more

CEO Gustav H. Gram increases holding in PILA PHARMA AB

Malmö, 02 September 2024 Download the press release as PDF here Pila Pharma AB (publ) (FN STO: PILA) announces that recently appointed CEO Gustav H. Gram has purchased additional shares. The purchases occurred on Wednesday, 30 August, where 29.375 shares in the company were acquired. The shares were purchased at an average price of SEK 5,1768.___Mr. Gram's direct holdings in Pila Pharma AB…

Read more

PILA PHARMA publishes interim report (1 January – 30 June 2024)

Malmö, 27 August, 2024 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for the period January - June 2024. The report can be found on the Company´s website: https://pilapharma.com/investors/finansiell-information/ SUMMARY OF INTERIM REPORT First Half year (1 January - 30 June 2024) Operating income amounted to TSEK 683 (1…

Read more

Contact us

Subscription for press releases
Back To Top